article thumbnail

The Inflation Reduction Act: The Impact of Medicare Negotiation of Prescription Drug Prices on Hospitals and Health Systems

Omnicell

Ken Perez Vice President of Healthcare Policy and Government Affairs, Omnicell In August, H.R. Since the drugs that would be negotiation-eligible for implementation in 2026 are unknown, and the prices that will be dictated by Medicare have not been set, modeling of the impact on the 340B Program is not feasible.

article thumbnail

Key Takeaways from New Medicare Law and Its Implications for 340B Stakeholders

Omnicell

Health and Human Services Department (HHS) will not be able to begin to negotiate drug prices until 2026, and only on 10 single-source drug products covered under the Medicare Part D program. Several of the most important measures don’t kick in for years. For instance, the U.S. Part D covers drugs dispensed at a pharmacy and taken home.